Can lung cancer patients skip a drug break for radiation?
NCT ID NCT05089916
Summary
This study aims to find out if it's safe and effective for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) to continue taking their daily oral medication, osimertinib, while also receiving radiation therapy. It involves 42 participants who need radiation to control a few growing tumors or to relieve symptoms. The main goal is to check for serious side effects when the drug and radiation are given together, to see if pausing the medication is necessary.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LMU Klinikum der Universität München
München, 80336, Germany
Conditions
Explore the condition pages connected to this study.